T-DM1 improved overall survival for heavily pretreated patients with HER2-positive br
Among patients with HER2-positive, metastatic breast cancer that had progressed despite treatment with two or more forms of HER2-targeted therapy (trastuzumab [Herceptin] and lapatinib [Tykerb])...